Skip to main content
S. 1544 118th Congress Senate

Facilitating Innovative Nuclear Diagnostics Act of 2023

Official title: A bill to amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, diagnostic radiopharmaceut… Show full official titleShow less

Official title: A bill to amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, diagnostic radiopharmaceuticals under the Medicare hospital outpatient prospective payment system.

Introduced: May 10, 2023 Introduced by: Marsha Blackburn Republican · Tennessee See on congress.gov
Health Health care costs and insuranceMedical tests and diagnostic methodsMedicareRadiation
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 10, 2023
Read twice and referred to the Committee on Finance.
May 10, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action May 10, 2023

Read twice and referred to the Committee on Finance.

 Plain-English summary Congressional Research Service

Facilitating Innovative Nuclear Diagnostics Act of 2023

This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2024 and as adjusted based on a specified fee schedule factor in each year thereafter.

 Related & companion bills 1
  • HR 1199 Identical bill Facilitating Innovative Nuclear Diagnostics Act of 2023
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 11

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 11 filings →
 Cosponsors 7
All 7 Democratic 4 Republican 3
R
Hyde-Smith, Cindy
Mississippi · Oct 25, 2023
 D
Shaheen, Jeanne
New Hampshire · Oct 25, 2023
 R
Collins, Susan M.
Maine · Oct 17, 2023
 D
Duckworth, Tammy
Illinois · Oct 17, 2023
 R
Capito, Shelley Moore
West Virginia · Jul 11, 2023
 D
Hassan, Margaret Wood
New Hampshire · Jul 11, 2023
 D
Baldwin, Tammy
Wisconsin · May 10, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1544: Facilitating Innovative Nuclear Diagnostics Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-1544/
MLA
"S. 1544: Facilitating Innovative Nuclear Diagnostics Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-1544/.
Bluebook (legal)
S. 1544, 118th Cong. (2026), https://openamerica.io/bill/118-S-1544/.
Markdown link
[S. 1544: Facilitating Innovative Nuclear Diagnostics Act of 2023](https://openamerica.io/bill/118-S-1544/)
Report a problem